In 2020, Mao and co‐workers used tumor‐homing angiogenin‐binding engineered phage nanofibers (fd388‐AR‐WV) to selectively reduce tumor angiogenesis, which implements targeted breast cancer therapy.[13] Specifically speaking, the filamentous fd phage (termed fd388) (Figure 9a,b) was first fabricated based on proteins and the core ssDNA. This evidence concerns the gene ANG and breast carcinoma.